Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Abnormal metabolism of cholesterol may be a contributing factor in nonalcoholic steatohepatitis (NASH) pathogenesis. Accumulating evidence has shown that liver X receptor (LXR) is closely related to intrahepatic inflammation and fibrosis. In this study, we evaluated the effects of a novel liver-specific LXR inverse agonist, SR9243, on antifibrosis in NASH mice. A high-cholesterol diet was employed to induce NASH in BALB/c mice by either carbon tetrachloride (CCL4) administration or bile-duct ligation (BDL). Once NASH was induced, mice were treated with SR9243 for one month by intraperitoneal (i.p.) injection. Liver tissues were collected to determine the degree of fibrosis and intrahepatic inflammation via pathological examination and QPCR; serum was collected to analyze the plasma lipid levels and liver function by clinical biochemistry. The mice developed hepatic steatosis, severe hepatic inflammation, and fibrosis by BDL or CCL4. Treatment with SR9243 significantly reduced the severity of hepatic inflammation and ameliorated hepatic fibrosis; simultaneously, body weight, serum glucose, and plasma lipid levels were controlled effectively. Our data demonstrate that SR9243 exerts an antifibrotic and anti-inflammatory effect in NASH mice; hence these findings highly suggest that LXR inverse agonist could be therapeutically important in NASH treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Paradoxically, the LXR inverse agonist SR9243 had similar beneficial anti-fibrotic and anti-inflammatory effects in two BASH (both-alcoholic and steatohepatitis) mouse models, which were induced by using a high-cholesterol diet in combination with either CCl 4 administration or bile-duct ligation.[167]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [167]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779 · cited 1×
“Previous studies have proved that LXRα is highly expressed in kidney, liver, intestines, and adipose tissue while LXRβ is expressed widespreadly throughout the body [8].”
Liver X receptors in lipid metabolism: opportunities for drug discovery
Hong, C., & Tontonoz, P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4280 · Cited by 587
Tomita, K., Tamiya, G., Ando, S., Ohsumi, K., Chiyo, T., Mizutani, A., Kitamura, N., Toda, K., Kaneko, T., Horie, Y., et al. (2006) · Gut · doi:10.1136/gut.2005.071118 · Cited by 438
Yang, H., Fang, F., Chang, R., & Yang, L. (2013) · Hepatology · doi:10.1002/hep.26315 · Cited by 261
Teratani, T., Tomita, K., Suzuki, T., Oshikawa, T., Yokoyama, H., Shimamura, K., Tominaga, S., Hiroi, S., Irie, R., Okada, Y., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.049 · Cited by 241
Targeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212
Flaveny, C. A., Griffett, K., El-Gendy, B. E.-D. M., Kazantzis, M., Sengupta, M., Amelio, A. L., Chatterjee, A., Walker, J., Solt, L. A., Kamenecka, T. M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.007 · Cited by 208
Miura, K., Seki, E., Ohnishi, H., & Brenner, D. A. (2010) · Gastroenterology Research and Practice · doi:10.1155/2010/362847 · Cited by 149
Cited by
Lin, H., Liu, Z., Yang, H., Lu, L., Chen, R., Zhang, X., Zhong, Y., & Zhang, H. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.2c03452 · Cited by 129
Dixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 125
Huang, P. F., Huang, F., Liu, H.-Z., Zhang, T., Yang, M., & Sun, C. (2019) · Metabolism · doi:10.1016/j.metabol.2019.01.018 · Cited by 102
Self-citationCarpenter, K. J., Valfort, A.-C., Steinauer, N., Chatterjee, A., Abuirqeba, S., Majidi, S., Sengupta, M., Di Paolo, R. J., Shornick, L. P., Zhang, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56038-1 · Cited by 65
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Metadata
- Authors
- Huang, P., Kaluba, B., Jiang, X.-L., Chang, S., Tang, X.-F., Mao, L.-F., Zhang, Z.-P., & Huang, F.-Z.
- Affiliations
- Central South University (CN)
- Yangtze University (CN)
- Department of General Surgery, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China
- Department of General Surgery, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Changsha 410013, China
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Pages
- 1-7
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC5835296
- OpenAlex
- W2789257932
- Cited by
- 44
- References
- 26
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 7
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Hunan Provincial Innovation Foundation for Postgraduate (CX2017B073)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- liver X receptor, nonalcoholic steatohepatitis, liver fibrosis, intrahepatic inflammation, cholesterol metabolism, bile duct ligation, carbon tetrachloride, high-cholesterol diet, hepatic steatosis, plasma lipid levels, antifibrotic therapy
- MeSH terms
- Liver X Receptors, Animals, Bile Ducts, Blood Glucose, Body Weight, Carbon Tetrachloride, Inflammation, Insulin, Ligation, Lipids, Liver, Liver Cirrhosis, Male, Mice, Inbred BALB C, RNA, Messenger, Sulfonamides, Cytokines, Inflammation Mediators, Hepatocytes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. https://app.cochat.ai/papers/10.1155/2018/8071093
- The paper
- Huang, P., Kaluba, B., Jiang, X.-L., Chang, S., Tang, X.-F., Mao, L.-F., Zhang, Z.-P., & Huang, F.-Z. (2018). Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. BioMed Research International. https://doi.org/10.1155/2018/8071093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.